GeneDx Holdings Corp. - Class A Common Stock (WGS)
34.51
-0.00 (-0.00%)
NASDAQ · Last Trade: May 6th, 5:16 AM EDT
Detailed Quote
Previous Close
34.51
Open
-
Bid
34.20
Ask
34.51
Day's Range
N/A - N/A
52 Week Range
55.17 - 170.87
Volume
13,477
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
592,873
Chart
About GeneDx Holdings Corp. - Class A Common Stock (WGS)
GeneDx Holdings Corp. is a genomics company that specializes in providing genetic testing services to aid in the diagnosis and treatment of various genetic disorders. By leveraging advanced genomic technologies and bioinformatics, the company aims to deliver accurate and comprehensive genetic information that helps clinicians make informed decisions about patient care. GeneDx focuses on enhancing the understanding of rare and hereditary diseases, facilitating personalized medicine, and improving patient outcomes through insightful genomic data services. Read More
The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diagnoses faster and guide clinical decision-making. De-identified data from the program will be added to GeneDx Infinity™, the largest and most comprehensive rare disease dataset, to help drive faster diagnoses of NPC to help patients and providers make informed treatment decisions.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation, novel gene-disease discoveries, the real-world impact of earlier diagnoses, and more.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:
